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See Article, pages 351–357While iron is essential for many vital functions, there
is no regulated means by which excess iron can be dis-
posed of in humans. Therefore, whenever body iron
exceeds its needs and storage capabilities are saturated,
toxicity due to iron overload may arise. Many causes
of iron overload in humans exist, both genetic and
acquired. Traditionally, hereditary hemochromatosis
and post-transfusion iron overload have been associated
with large hepatic iron deposits. However, an increasing
number of other conditions are being recognized in
which an observed mild or moderate increase of iron
stores may have signiﬁcant clinical relevance [1]. These
conditions include alcoholic and non-alcoholic fatty
liver disease (ALD and NAFLD, respectively) and ste-
atohepatitis (ASH and NASH, respectively), chronic
hepatitis C, and end-stage liver disease (Table 1). In this
issue of the Journal, Sorrentino et al. [2] have investi-
gated the relationship between hepatic iron and the
development of HCC in NASH patients. Raised hepatic
iron seems to increase the risk for NASH or its progres-
sion [3,4]. Hyperinsulinemia is a risk factor for the devel-
opment of NASH and the coexistence of iron may
contribute to the development of insulin resistance
[5,6], while iron removal by phlebotomy can improve
the insulin resistance and liver function in patients with
NAFLD [7]. While there is little doubt that diﬀerent
chronic liver diseases, including NASH, can be accom-0168-8278/$34.00  2008 European Association for the Study of the Liver.
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(Table 1), the question is whether such a marginal
increase of tissue iron is clinically meaningful.
Normal hepatic iron content, as assessed by chemical
methods, is usually below 35 lmol/g of dry weight. His-
torically, HIC above 200–250 lmol/g of dry weight has
been associated with liver ﬁbrosis and cirrhosis in hemo-
chromatosis and thalassemia [8,9]. However, the actual
hepatic iron burden in NASH (and other chronic liver
disease patients), is far below that threshold. Neverthe-
less, even the presence of mild iron excess in the liver
represents a risk for toxicity: iron can act as a comorbid
factor (along with fat, hepatitis viruses and alcohol), and
fuel oxidative stress-driven cell toxicity, or signalling
pathways involved in ﬁbrogenesis and carcinogenesis
[10].
In chronic liver diseases, iron deposits are found
either in hepatocytes, Kupﬀer/sinusoidal cells, or in
both. Iron excess in hepatocytes leads to oxidative
stress, cell toxicity and genotoxicity (Fig. 1A). Hepato-
cytic iron usually reﬂects increased iron inﬂux as a con-
sequence of circulatory iron excess. A recognized cause
for increased iron inﬂux is hepcidin deﬁciency due to
either genetic (e.g. C282Y HFE mutation) or acquired
(e.g. alcohol, HCV etc.) factors [11] (Table 1). On the
other hand, iron accumulation in Kupﬀer cells (histori-
cally attributed to phagocytosis of necrotic hepatocytes)
may have another signiﬁcance, but similar eﬀects
(Fig. 1B). Kupﬀer cells, naturally devoted to erythro-
phagocitosis, are likely better equipped than hepatocytes
to handle excess iron and more comfortable with intra-
cellular movements of free radicals (which are normally
used by macrophages to kill pathogens). Nevertheless,
whatever the cause, iron engulfed sinusoidal-KupﬀerPublished by Elsevier B.V. All rights reserved.
Table 1
Chronic liver diseases usually associated with detectable hepatic iron deposits.
Disease Known or postulated causes for iron excess Known or postulated eﬀects of iron excess
NASH/NAFLD  Necroinﬂammation  Insulin resistance
 Disease progression
 HCC
Chronic viral hepatitis  Necroinﬂammation
 Hepcidin down-regulation
 Disease progression
 Impaired response to antiviral drugs
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lying liver disease and development of its complications.
Excess iron deposits in Kupﬀer/sinusoidal cells may
aﬀect their immunomodulatory and inﬂammatory activ-
ity, cytokine biology, defense against pathogen and viral
infection, immunosurveillance of tumor growth, or
response to immunomodulatory drugs (Fig. 1B) [12].
Obviously, this consideration takes us to another ques-
tion: does it only matter ‘‘how much” iron accumulates
in the liver, or is it ‘‘where” iron deposits are located
that makes the diﬀerence for disease progression? A sim-
ple way for quantifying hepatic iron excess and also gain
information on iron distribution is staining biopsy spec-
imen for iron by Perls’ stain. The Scheuer-based iron
grading systems have used the Perls’ stain to score the
percentage of iron loaded hepatocytes [13,14]. A more
sophisticated method proposed by Deugnier [15] takes
into account iron deposits in parenchymal, sinusoidal
cells and in portal tracts, and oﬀers a good opportunity
to assess iron deposits and its cell distribution. In the
article by Sorrentino et al. [2] hepatic iron deposits have
been assessed retrospectively using the Deugnier Score
(range 0–60) in 153 patients with NASH-related cirrho-
sis: 51 with and 102 without HCC, matched for age, sex
and stage of liver disease. As expected, many patients
with NASH had iron deposits in the biopsy, but the
majority scored below, and none above 33. Interestingly,Fig. 1. Known or postulated eﬀects of hepatocytic or Kupﬀer cell iron on
chronic liver disease progression and HCC development.the iron score was signiﬁcantly higher in HCC-NASH
patients than in HCC-free NASH controls, and, more
importantly, in the former group, liver ‘‘iron overload”
was mainly sinusoidal. Although the study suﬀers from
obvious ﬂaws due to its retrospective design and the lack
of mechanistic clues, it clearly underscores the strict
association between iron deposits and HCC develop-
ment in NASH, and stresses the pathogenic role of
‘‘sinusoidal” iron deposits. Interestingly, a recent pro-
spective study in 301 consecutive cirrhotics found that
in patients with alcoholic cirrhosis liver iron ‘‘overload”
(mean score 2.0 ± 3.0 according to a modiﬁed version of
Deugnier’s method) was independently associated with a
higher risk of HCC [16]. Unfortunately, no information
was given on the eﬀect of sinusoidal vs. hepatocytic iron
deposits on HCC development.
What are the take-home messages? First, positive
iron stain in a liver biopsy is important. Although the
term ‘‘iron overload” as used in hemochromatosis and
thalassemia may not be appropriate, the detectable pres-
ence of hepatic iron deposits in the biopsy of patients
with chronic liver diseases does indicate a condition that
is not normal and potentially deleterious. Second, there
may be a pathogenic role of sinusoidal iron accumula-
tion in the progression of chronic liver diseases and/or
HCC development. Overall, does this mean that ‘‘no
detectable iron” in a liver biopsy is good, and ‘‘any” iron
stain is bad? Maybe . . .but to conclusively answer this
and other related key questions we need large prospec-
tive studies in selected groups of patients with chronic
liver diseases where the independent pathogenic role of
hepatic iron deposits is evaluated, also taking into
account epidemiologic factors that are known to be
associated with both iron imbalance and disease pro-
gression/HCC, such as age and male gender. Hopefully,
this will pave the way for controlled clinical trials using
iron removal strategies/iron chelators to prove that low-
ering hepatic iron deposits prevents liver disease pro-
gression and its complications, including HCC.
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